TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 and older of any gender, ethnicity and race~* Voluntary enrollment and ability to give written informed consent~* Capable of safely undergoing endoscopy with deep sedation or general anesthesia~* Patients with previously-detected pancreatic cyst(s) 1-5 cm in diameter, including indeterminate cysts~Exclusion Criteria:~* Pancreatic cyst \<1cm or \>5cm~* Pancreatic cyst with clear communication with main pancreatic duct~* Clearly benign lesions by clinical and radiographic evaluation (pseudocysts and serous cystadenomas)~* Known or suspected pancreatic cancer or pathologic lymphadenopathy~* Septated cysts with \> 5 compartments~* Coagulopathy (international normalized ratio \> 1.6, platelets \< 30,000)~* Evidence of active pancreatitis or pancreatic infection~* Patients having undergone endoscopic retrograde cholangiopancreatography (ERCP) within 72 hours~* Baseline lab values at the time of consent: white blood cells \> 14 or \< 2, hematocrit \< 30, platelets \< 30,000, INR \> 1.6, abnormal CA19-9, lipase \> 3 times the upper limit of normal, creatinine \> 2.5, ALT \> 210, total bilirubin \> 2.5, positive qualitative beta-hCG.~* Any pre-existing or discovered medical condition that may, at the discretion of the investigator, interfere with the completion of and/or participation in the existing protocol.~* Pregnant, breastfeeding, or incarcerated individuals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Cyst will be lavaged for 3-5 minutes with Ethanol (alcohol 80%). Following lavage with Ethanol (alcohol 80%), The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
- Study Group (Type: EXPERIMENTAL): Cyst will be lavaged for 3-5 minutes with Normal Saline .. Following lavage with Normal Saline, The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization \[WHO 2000\] classification).~* Disease progression within 12 months prior to study enrollment.~* Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.~Exclusion Criteria:~* Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification).~* Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sunitinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent and authority statement provided according to local regulatory and ethical practice using a participant information sheet and informed consent form approved by the responsible Ethics Committee.~* HIV-seropositive individuals.~Exclusion Criteria:~* Pregnancy as determined by a positive urine beta-hCG (if female)~* Participant unwilling to use reliable contraception methods for the duration of the trial. Reliable methods of birth control include: pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; surgical sterilization; vaginal ring; intrauterine device; abstinence; and post-menopause (if female)~* Currently breast-feeding (if female)~* Latest CD4 count \< 200 x106 cells/µL~* Viral load (HIV RNA) \> 50 copies/mL if on HAART (defined as at least three antiretrovirals including either a protease inhibitor or a NNRTI, i.e. combivir 300/150 mg x2 + stocrin 600 mg x1 for a minimum of 6 months)~* Previous enrollment in this study~* Any medical, psychiatric, social, or occupational condition or other responsibility that, in the judgment of the Principal Investigator (PI), would interfere with the evaluation of study objectives (such as severe alcohol abuse, severe drug abuse, dementia)~* Unable to follow protocol regimen~* Pneumococcal vaccination 5 years or less prior to inclusion~* Planned participation in other vaccination trials during the time of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 1 mg CpG 7909 + pneumococcal vaccines
- B (Type: PLACEBO_COMPARATOR): Pneumococcal vaccines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dupilumab for Severe Asthma in a Real Life Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* French patient with Severe Asthma~* Administration of dupilumab under the TUA between September 2017 and January 2018, with at least one injection~* Realization of at least one follow-up visit in the first 12 months of treatment~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal woman who seeks treatment for hot flushes.~* Meets 1 of the following: At least 12 months of spontaneous amenorrhea; At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \> 40 mIU/mL; At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy). Hysterectomized without bilateral oophorectomy and with serum FSH levels \>40 mIU/mL.~Exclusion Criteria:~* History of a seizure disorder other than a single childhood febrile seizure.~* History or presence of clinically important hepatic or renal disease or other medical disease.~* Presence or recent history of major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder requiring therapy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: ACTIVE_COMPARATOR): None
- D (Type: ACTIVE_COMPARATOR): None
- E (Type: ACTIVE_COMPARATOR): None
- F (Type: ACTIVE_COMPARATOR): None
- G (Type: ACTIVE_COMPARATOR): None
- H (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects diagnosed of HBeAg positive or negative chronic hepatitis B~2. Aged 18 to 70 years old，male or female~3. Patients with previously HBsAg-positive, HBeAg-positive for 24 weeks, HBV-DNA\> 105copies/ml. HBeAg-negative for 24 weeks or more, HBV-DNA\> 105 copies/ml.~4. 1.3 times the upper normal limit (1.3 × ULN) ≤ alanine aminotransferase (ALT) ≤ 10 × ULN.~5. Total serum bilirubin (TBIL) ≤ 2.5 × ULN.~6. Prothrombin activity (PTA) ≥ 60% or prothrombin time prolonged than normal ≤ 3 seconds).~7. WBC ≥ 3.5 × 109 / L, PLT ≥ 70 × 109 / L, serum albumin (ALB)≥ 35 g / L.~8. Creatinine (Cr) ≤ 1.5 × ULN.~9. If patients take intermittently with interferon, nucleoside (acid) analogues, α1 thymosin before enrollment with 24 weeks, the time is no more than 12 weeks.~10. Patients signed an informed consent form and compliance was good.~Exclusion Criteria:~1. Patients were infected with other viruses as HAV, HCV, HDV, HEV, CMV, EBV, HIV etc.~2. Patients with cirrhosis or liver cancer.~3. Patients have participated in another therapeutic clinical trial in 3 months.~4. Granulocyte count \<1.5 × 109 / L, hemoglobin (HB)\<100g / L, sera alpha-fetoprotein(AFP)\> 100μg / L, patients' B ultrasonography pointed space-occupying lesions.~5. Patients with severe heart, kidney, endocrine hematopoietic system and neuropsychiatric diseases.~6. Patients with metabolic or autoimmune diseases such as systemic lupus erythematosus.~7. Pregnant woman, lactating women or those who wre allergic for study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- HBeAg positive group (Type: OTHER): Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .
- HBeAg-negative group (Type: OTHER): Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Scalpel vs Diathermy in Repeat Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Multiparous pregnant women 18 - 45 years.~* Gestational ages 37 weeks to 41 weeks,~* Undergoing repeat elective or repeat emergency cesarean deliveries.~Exclusion Criteria:~* Informed consent can't be obtained in a manner that allows for no impression of undue influence/pressure or sufficient time for patient to consider participation.~* Primary Cesarean deliveries - as these can bias the selection.~* Skin conditions such as infections, psoriasis, and eczema.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- scalpel group (Type: ACTIVE_COMPARATOR): Scalpel is the device used to make abdominal wall incision in this group of patient.
- Diathermy group (Type: ACTIVE_COMPARATOR): In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~At dose 1~* Healthy male or female, 18 to 40 years of age,~* Free of disease,~* Written informed consent obtained from subjects. At dose 2~* Received dose 1.~* Oral informed consent obtained from subject for continuing participate the study.~Exclusion Criteria:~At dose 1~1. Pregnant woman or planning to be pregnant during the study period.~2. Has a chronic disease (cardiovascular, liver, kidney disease).~3. Acute disease at the time of enrolment.~4. Administering corticosteroids (\> 1mg/kg/day).~5. Received any immunosuppressive therapy within 4 week before vaccination (Administration of immunoglobulins and/or any blood product or corticosteroids for \>2 weeks).~6. Immunosuppressive or immunodeficient condition.~7. Allergic or reaction with any component of vaccine, includes anaphylactic and shock with any antibiotic.~8. Fever (axillary temperature \>38oC) within 3 days before or on the day of vaccination.~9. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.~10. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine during the study period.~At dose 2~1. Pregnant woman or planning to be pregnant in next 1 month.~2. Acute disease at the time of 2nd dose.~3. Administering corticosteroids (\> 1mg/kg/day).~4. Received any immunosuppressive therapy within 4 week before vaccination (administration of immunoglobulins and/or any blood product or corticosteroids for \>2 weeks).~5. Immunosuppressive or immunodeficient condition.~6. History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.~7. Fever (axillary temperature \>38oC) within 3 days before or on the day of vaccination.~8. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.~9. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Rotavin (Type: EXPERIMENTAL): Rotavin-M1 vaccine, 10e6.3FFU/dose, 2 doses, 1 month between doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pakistani muslim male / female, type 2 diabetic patient having age from 18 years to 75 years~* Patient who give informed consent voluntarily~* BMI ≤45 kg/m2~* Glycosylated hemoglobin of 7 - ≤10%~Exclusion Criteria:~* Patients who are on empagliflozin treatment~* Indication of liver disease, defined by serum levels of either alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase above 3 times upper limit to normal~* Estimated glomerular filtration rate (eGFR) \<45 mL /min /1.73m2~* History of recurrent urinary tract infection (UTI) and/or past 3 months' history of UTI and its treatment~* Patients with positive urine culture for UTI at the time of screening~* Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state~* Patients with past 3 months' history of fungal infection and its treatment~* History of blood dyscrasias or any disorders causing haemolysis or unstable red blood cell~* History of benign prostate hyperplasia~* Any acute coronary syndrome, stroke and/or transient ischemic attack (TIA) in the previous 3 months~* Any contraindication for patients to Biguanides, Sulfonylureas, DPP-IV inhibitors, SGLT-2 Inhibitors~* Treatment with anti-obesity drugs or any other treatment leading to unstable body weight~* Patients with past 6 weeks treatment history with systemic steroids or thyroid hormones or any other uncontrolled endocrine disorder except T2DM~* Pre-menopausal women who are nursing or pregnant or are of childbearing potential and not practicing an acceptable method of birth control~* Any other clinical condition that would jeopardize patients safety while participating in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): None
- Usual Care Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male heterosexual patients aged 22-70 years.~* Confirmed clinical diagnosis of mild, moderate or severe ED for more than 3 months.~* Involved in a continuous heterosexual relationship with their partner for at least 6 months.~Exclusion Criteria:~* Any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease.~* History of unstable medical or psychiatric condition or using any medication that, in the opinion of the Principal Investigator, is likely to affect the patient's ability to complete the investigation or precludes the patient's participation in the investigation.

- Gender: MALE
- Minimum Age: 22 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MED3000 (Type: EXPERIMENTAL): MED3000 gel formulation topically applied to the glans penis
- Tadalafil (Type: EXPERIMENTAL): Tadalafil (5 mg) tablets to be taken orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to screening~2. Confirmed prior virological failure with an approved dose of PegIFN/RBV~3. Age 18 to 70 years,~4. HCV RNA (RiboNucleic Acid) = 1,000 IU/mL at screening,~Exclusion criteria:~1. HCV infection of mixed genotype; Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV) co-infection~2. Evidence of acute or chronic liver disease due to causes other than chronic HCV infection,~3. Decompensated liver disease, or history of decompensated liver disease,~4. Body weight \< 40 or \> 125 kg,~5. Clinical evidence of significant or unstable cardiovascular disease, chronic pulmonary disease, history or evidence of retinopathy or clinically significant ophthalmological disorder~6. Pre-existing psychiatric condition that could interfere with the subject's participation in and completion of the study~7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or G6PD deficit)~8. Hemoglobin \< 12 g/dL for women and \< 13 g/dL for men~9. Patients who have been previously treated with at least one dose of any antiviral or immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV infection including and not restricted to protease or polymerase inhibitors,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/PegIFN/RBV (Type: ACTIVE_COMPARATOR): patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
- BI201335 12 weeks (Type: EXPERIMENTAL): patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks
- BI201335 24 weeks (Type: EXPERIMENTAL): patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients 18 years old or older.~* Patients with a diagnosis of hypertension defined as follows:~  * Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP \>= mmHg and \< 110 mmHg at Visit 1.~ * All patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP \>= 85 mmHg and \< 110 mmHg at Visit 2.~ * All patients must have a msDBP \>= 90 mmHg and \< 110 mmHg at Visit 5.~* Patients who are eligible and consent to participate in the study~Exclusion Criteria:~* Severe hypertension (msDBP \>= 110 mmHg and/or MSSBP \>=180 mmHg).~* Previous or current diagnosis of heart failure.~* History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack, myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention.~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete